Most Read Articles
20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.
Audrey Abella, 21 Dec 2018
Use of a single course of the intravenous iron preparation ferumoxytol may lead to sustained improvements in patient-reported outcomes (PROs) of individuals with iron deficiency anaemia (IDA) who had inadequate response to oral iron therapy, according to data presented at ASH 2018.
Saras Ramiya, 23 Oct 2018
The Malaysian Pharmacy Students’ Association (MyPSA) has successfully organized the 13th National Gathering of Pharmacy Students (NoGAPS) in September.
Audrey Abella, 13 Dec 2018
The combination of the monoclonal antibody rituximab and the immunomodulatory agent lenalidomide (R2 regimen) showed significant survival advantage over single-agent rituximab in patients with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL), which includes follicular lymphoma (FL) and marginal zone lymphoma (MZL), according to the results of the AUGMENT* trial presented at ASH 2018.

Postdiagnosis statin use cuts risk of death in hepatocellular carcinoma

02 Feb 2019

Use of statins following diagnosis of hepatocellular carcinoma (HCC) appears to confer survival advantage, a study reports.

Researchers looked at 15,422 patients with HCC in the VA Central Cancer Registry. They identified statin prescriptions filled prior to and after cancer diagnosis and used time-dependent Cox regression models to estimate mortality risk. Meanwhile, a time-varying exposure was applied to avoid immortal-time bias, with a 3-month lag (following patients from 3 months after cancer diagnosis) to reduce reverse causation.

Of the patients, 14.9 percent used statin following diagnosis. Postdiagnosis statin use was associated with a 15-percent reduction in the risk of cancer-specific mortality (adjusted hazard ratio [aHR], 0.85; 95 percent CI, 0.77–0.93) and an 11-percent reduction in all-cause mortality (aHR, 0.89; 0.83–0.95).

The beneficial effect of postdiagnosis statin use on survival was consistent for HCC patients using both low- and high-dose statins and remained across a range of lag periods (0–12 months after HCC diagnosis).

There was no evidence for effect modification by prediagnosis statin use, presentation or treatment-related factors. Finally, prediagnosis statin use showed no association with mortality.

Statins have been reported to protect against the risk of developing HCC, researchers noted. The present data add to existing literature and suggest that the drug provides survival gains in HCC patients.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.
Audrey Abella, 21 Dec 2018
Use of a single course of the intravenous iron preparation ferumoxytol may lead to sustained improvements in patient-reported outcomes (PROs) of individuals with iron deficiency anaemia (IDA) who had inadequate response to oral iron therapy, according to data presented at ASH 2018.
Saras Ramiya, 23 Oct 2018
The Malaysian Pharmacy Students’ Association (MyPSA) has successfully organized the 13th National Gathering of Pharmacy Students (NoGAPS) in September.
Audrey Abella, 13 Dec 2018
The combination of the monoclonal antibody rituximab and the immunomodulatory agent lenalidomide (R2 regimen) showed significant survival advantage over single-agent rituximab in patients with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL), which includes follicular lymphoma (FL) and marginal zone lymphoma (MZL), according to the results of the AUGMENT* trial presented at ASH 2018.